Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: Role of PPAR-α and SREBP-1c

Journal of Nutritional Biochemistry

Volumn 25, Issue 9, 2014, Pages 977-984

  Dossi, Camila G ^a   Tapia, Gladys S ^a   Espinosa, Alejandra ^b   Videla, Luis A ^a   D'Espessailles, Amanda ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

High fat diet; Liver steatosis; N 3 Long chain polyunsaturated fatty acid; PPAR ; SREBP 1c

Indexed keywords

DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TUMOR NECROSIS FACTOR ALPHA; OMEGA 3 FATTY ACID; PRIMER DNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIET SUPPLEMENTATION; FAT CONTENT; FATTY LIVER; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; ANIMAL; C57BL MOUSE; LIPID DIET; METABOLISM; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

MUS;

ANIMALS; BASE SEQUENCE; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DNA PRIMERS; FATTY ACIDS, OMEGA-3; FATTY LIVER; MALE; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; PPAR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84905218869     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.04.011     Document Type: Article

References (50)

1. Malaguarnera M., Di Rosa M., Nicoletti F., Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med 2009, 87:679-695.
2. Videla L.A., Rodrigo R., Araya J., Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006, 12:555-558.
3. Cave M., Deaciuc I., Mendez C., Song Z., Joshi-Barve S., Barve S., et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007, 18:184-195.
4. Browning J., Horton J. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 14:147-152.
5. Pettinelli P., Obregón M., Videla L. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutr Hosp 2011, 26:441-450.
6. Aronis A., Madar Z., Tirosh O. Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic Biol Med 2005, 38:1221-1230.
7. Gaggini M., Morelli M., Buzzigoli E., DeFronzo R.A., Bugianesi E., Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013, 5(5):1544-1560. 10.3390/nu5051544.
8. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: executive summary. Crit Pathw Cardiol 2005, 112:2735-2752.
9. Araya J., Rodrigo R., Videla L.A., Thielemann L., Orellana M., Pettinelli P., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004, 106:635-643.
10. Masi L.N., Rodrigues A.C., Curi R. Fatty acids regulation of inflammatory and metabolic genes. Curr Opin Clin Nutr Metab Care 2013, 16:418-424.
11. Goto T., Kim Y.-I., Takahashi N., Kawada T. Natural compounds regulate energy metabolism by the modulating activity of lipid-sensing nuclear receptors. Mol Nutr Food Res 2013, 57:20-33.
12. Videla L.A., Pettinelli P. Misregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity. PPAR Res 2012, 10.1155/2012/107434.
13. Yamamoto K., Itoh T., Abe D., Shimizu M., Kanda T., Koyama T., et al. Identification of putative metabolites of docosahexaenoic acid as potent PPAR-γ agonists and antidiabetic agents. Bioorg Med Chem Lett 2005, 15:517-522.
14. González-Périz A., Planagumá A., Gronert K., Miquel R., López-Parra M., Titos E., et al. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J 2006, 20:1845-1855.
15. Fernández V., Tapia G., Videla L.A. Recent advances in liver preconditioning: thyroid hormone, n-3 long-chain polyunsaturated fatty acids and iron. World J Hepatol 2012, 4:119-128.
16. Nobili V., Sanyal A.J. Treatment of nonalcoholic fatty liver disease in adults and children: closer look at the arsenal. J Gastroenterol 2012, 47:29-36.
17. Valenzuela R., Espinosa A., González D., Fernández V., Videla L.A., Romanque P., et al. N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. PLoS ONE 2012, 7(10):e46400. 10.1371/journal.pone.0046400.
18. Anstee Q.M., Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006, 87:1-16.
19. Brunt E.M., Janney C.G., Di Biscegle A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and b-cell function from fasting glucose and insulin concentration in man. Diabetologia 1985, 28:412-419.
21. Reznick A.Z., Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994, 233:357-363.
22. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
23. Morrison W.R., Smith L.M. Preparation of fatty acid methyl esters and dimethylacetals from lipids with fluoride-methanol. J Lipid Res 1964, 5:600-608.
24. Surwit R.S., Kuhn C.M., Cochrane C., McCubbin J.A., Feinglos M.N. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988, 37:1163-1167.
25. De Meijer V., Le H., Meisel J., Sharif M., Pan A., Nosé V., et al. Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism 2010, 59:1092-1105.
26. Ruzickova J., Rossmeisl M., Prazak T., Flachs P., Sponarova J., Veck M., et al. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids 2004, 39:1177-1185.
27. Litman B.J., Mitchell D.C. A role for phospholipid polyunsaturation in modulating membrane protein function. Lipids 1996, 31:193-197.
28. Stillwell W., Shaikh S.R., Zerouga M., Siddiqui R., Wassall S.R. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev 2005, 45(5):559-579.
29. D'Alessandro M.E., Chicco A., Lombardo Y.B. Fish oil reverses the altered glucose transporter, phosphorylation, insulin receptor substrate-1 protein level and lipid contents in the skeletal muscle of sucrose-rich diet fed rats. Prostaglandins Leukot Essent Fatty Acids 2013, 88:171-177. 10.1016/j.plefa.2012.11.003.
30. Taouis M., Dagou C., Ster C., Durand G., Pinault M., Delarue J. N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. Am J Physiol Endocrinol Metab 2002, 282(3):E664-E671.
31. Samane S., Christon R., Dombrowski L., Turcotte S., Charrouf Z., Lavigne C., et al. Fish oil and argan oil intake differently modulate insulin resistance and glucose intolerance in a rat model of dietary-induced obesity. Metabolism 2009, 58(7):909-919. 10.1016/j.metabol.2009.02.013.
32. Peyron-Caso E., Fluteau-Nadler S., Kabir M., Guerre-Millo M., Quignard-Boulangé A., Slama G., et al. Regulation of glucose transport and transporter 4 (GLUT-4) in muscle and adipocytes of sucrose-fed rats: effects of N-3 poly- and monounsaturated fatty acids. Horm Metab Res 2002, 34(7):360-366.
33. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009, 48:1-26.
34. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440:944-948.
35. Demoz A., Willumsem N., Berge R.K. Eicosapentaenoic acid at hypotriglyceridemic dose enhances the hepatic antioxidant defense in mice. Lipids 1992, 27:968-971.
36. Gao I., Wang J., Sekhar K.R., Yin H., Yared N.F., Schneider S.N., et al. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem 2007, 282:2529-2537.
37. Singh S., Vrishni S., Singh B.K., Rahman I., Kakkar P. Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic Res 2010, 44:1267-1288.
38. Ferré P., Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010, 12:83-92.
39. Spadaro L., Magliocco O., Spampinato D., Piro S., Oliveri C., Alagona C., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008, 40:194-199.
40. Pettinelli P., del Pozo T., Araya J., Rodrigo R., Araya A.V., Smok G., et al. Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 2009, 1792:1080-1086.
41. Malaguarnera L., Di Rosa M., Zambito A.M., dell,Ombra N., Nicoletti F., Malaguarnera M. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut 2006, 55:1313-1320.
42. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., Cummins A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia, and tumor necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
43. Rensen S.S., Slaats Y., Nijhuis J., Jans A., Bieghs V., Driessen A., et al. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol 2009, 175:1473-1482.
44. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
45. Abdelmegeed M.A., Yoo S.H., Henderson L.E., Gonzalez F.J., Woodcroft K.J., Song B.J. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 2011, 141:603-610.
46. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048-32054.
47. de Roos B., Mavrommatis Y., Brouwer I.A. Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol 2009, 158:413-428.
48. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003, 278:14677-14687.
49. Ye D., Zhang D., Oltman C., Dellsperger K., Lee H.C., Van Rollins M. Cytochrome P-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J Pharmacol Exp Ther 2002, 303:768-776.
50. Shapiro H., Tehilla M., Attal-Singer J., Bruck R., Luzzatti R., Singer P. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr 2011, 30:6-19.